- You can view the full Johnson & Johnson Ratings Report.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
The pharma giant lost its third trial over claims that its talcum powder can cause ovarian cancer, but share prices remain unchanged.
The medical devices company is likely to stick to small- to mid- sized M&A unless it finds itself the target.
Johnson & Johnson (JNJ), McKesson (MCK), Merck (MRK) and UnitedHealth (UNH) benefit from demographic trends and have solid fundamentals.
The health care sector's ties to the increasingly unpopular Affordable Care Act, plus an uncertain U.S. presidential picture, give some financial experts pause.